PLX5622 hemifumarate NEW
| Price | $1168 |
| Package | 200mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-15 |
Product Details
| Product Name: PLX5622 hemifumarate | Supply Ability: 10g |
| Release date: 2025/05/15 |
Product Introduction
Bioactivity
| Name | PLX5622 hemifumarate |
| Description | PLX5622 hemifumarate is a highly selective, brain-penetrant, and orally active CSF1R inhibitor with an IC50 of 0.016 μM and Ki of 5.9 nM. It allows for extended and specific microglial elimination preceding and during pathology development and demonstrates desirable PK properties in various animals [1] [2]. |
| In vitro | PLX5622 hemifumarate (1-20 μM; 3 days) effectively depletes microglia without affecting oligodendrocytes or astrocytes in cerebellar slices. At 4 μM for 3 days, it reduces NG2+ or PDGFRα+ cells by 30-40%, increasing to 90-95% at 20 μM. No reduction in NG2+ or PDGFRα+ OPCs is observed at 1 μM or 2 μM PLX5622 despite robust (~95%) depletion of microglial cells [3]. |
| In vivo | In preclinical studies, PLX5622 hemifumarate demonstrates significant microglial depletion in adult C57/Bl6 wild-type mice when administered at 1200 ppm in chow for durations of 3 days to 3 weeks, resulting in approximately 80% reduction after 3 days, and a 99% reduction after 3 weeks. Similar outcomes were observed in different brain regions including the cortex, striatum, cerebellum, and hippocampus when administered for 3 weeks. Intraperitoneal injections of 50 mg/kg in neonatal and adult rats for 14 days resulted in 80-90% microglia depletion within the first 3 days, surpassing 90% by day 7, and achieving more than 96% depletion by day 14, while astrocyte levels remained unchanged. Notably, neonates required only a single daily injection, while adults needed twice-daily injections for effective depletion. Furthermore, administration of PLX5622 in AIN-76A chow at 1200 mg/kg for 28 days significantly reduced microglia in the CNS of 14-month-old 5xfAD mice. The pharmacokinetic profile of PLX5622 across various species revealed differences in bioavailability, clearance, and half-life, notably demonstrating efficient absorption and clearance rates. For gavage dosing preparations, PLX5622 hemifumarate is dissolved in DMSO, mixed with a diluent consisting of hydroxypropyl methyl cellulose and Polysorbate 80, and sonicated to achieve a uniform suspension for administration. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (220.53 mM), Sonication is recommended. |
| Keywords | PLX-5622 Hemifumarate | PLX-5622 hemifumarate | PLX5622 hemifumarate | PLX5622 Hemifumarate | PLX-5622 | PLX5622 | PLX 5622 Hemifumarate | PLX 5622 | CSF1R | cFms |
| Inhibitors Related | c-Fms-IN-3 | PLX5622 | PLX647 | Sotuletinib | GW2580 | Pexidartinib | c-Fms-IN-13 | GW786034B | Linifanib | Masitinib | Cerdulatinib hydrochloride | JNJ-6204 |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $150.00/1KG |
VIP3Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2023-10-07 | |
| $97.00/5mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-16 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $1168.00/200mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY